Navigation Links
Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study

End of Phase II meeting request as well as finalize the initial draft of a Phase III protocol, both of which we anticipate filing with the FDA in the first half of 2014," said Kevin C. Gorman, President and Chief Executive Officer of Neurocrine. "Our Phase II studies of NBI-98854 have served to define the study population, elucidate the primary endpoint, refine our dosing regimen and provide the necessary efficacy and safety data to enable pivotal studies."

The pre-specified statistical analysis plan included three data sets: a safety set (all subjects with at least one dose), an ITT set (all subjects who had an AIMS assessment at Week 6) and a PP set (all ITT subjects except those with no detectable drug levels at the evaluation time point). The table below summarizes the primary endpoint, LS Mean change-from-baseline AIMS, for both the ITT and PP populations at Week 6, as well as the responder analyses.Week 6PlaceboNBI-98854p-valueAIMS Change from BaselineBaseline AIMS






<0.001LS Mean AIMS ANCOVA (PP)



<0.001Responder Rate (ITT)*



0.002Responder Rate (PP)*



<0.001* a responder is defined as 50% or greater reduction in AIMS

The table below summarizes the key secondary endpoint, CGI-TD, for both the ITT and PP populations at Week 6.Week 6CGI-TDPlaceboNBI-98854p-valueLS Mean Score (ITT)



<0.001LS Mean Score (PP)



<0.001Responder Rate (ITT)*



<0.001Responder Rate (PP)*



<0.001*a responder is defined as "much improved" or "very much improved" (a "2" or "1", respectively) on the CGI-TD.  A "4" on the CGI-TD indicates "no change"

Subject ProfileThe Ki

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neurocrine Biosciences To Present At Oppenheimers 24th Annual Healthcare Conference
2. Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results
3. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
4. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
5. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
6. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
7. Neurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare Conference
8. Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference
9. Neurocrine Biosciences Reports First Quarter 2013 Results
10. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
11. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
Post Your Comments:
(Date:10/9/2015)...   --> ... San Diego, California , by Dr. ... NYU Lutheran Medical Center, on 9 th October 2015 at ... by Dr. Tom Lyon , Director of Orthopaedics and Chief ... October 2015 at 8:30a.m. PDT. --> Kuros Biosurgery AG, ...
(Date:10/9/2015)... Der " JCA-Mauvernay Award   ... und Dr.   Junko Takita    --> ... geht an Dr.   Yutaka Kondo und Dr.   ... " JCA-Mauvernay Award   2015 " geht an ...    ™ , das weltweit tätige Schweizer Biopharmazieunternehmen, wird ...
(Date:10/8/2015)... BRUNSWICK, N.J. , Oct. 9, 2015 Johnson ... of a safety and immunogenicity clinical trial in ... in development at its Janssen Pharmaceutical Companies. Trial recruitment is ... dose. This is the first study conducted of Janssen,s Ebola ... the recent Ebola epidemic. Sierra Leone,s ...
Breaking Medicine Technology:
... 2011 announces that a new market ... Assistive Devices for Special Needs: Technologies ... THIS REPORT CONTAINS ... products for several categories of special needs, including ...
... announces that a new market research report is ... Analytical Technologies for Pharmaceuticals: Global Markets ... market for process analytical technology (PAT) instrumentation was ... market is expected to increase by a 7.4% ...
Cached Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... Prescription Hope, ... all walks of life to save money on the high cost of their ... month per medication, individuals and families can receive their medications delivered direct from ...
(Date:10/9/2015)... ... October 09, 2015 , ... ViewPoint Center, a teen mental ... teenagers facing mental illness, the stigma associated with mental illness causes many to hide ... understands the importance of supporting teens with mental illness , providing teens with ...
(Date:10/9/2015)... ... 09, 2015 , ... Ryan Fox, the founder and CEO ... Colorado, says the latest figures on the state’s sales of legalized marijuana acknowledge ... industry. , Last month, according to the website , Colorado's ...
(Date:10/9/2015)... ... 09, 2015 , ... Amada Senior Care, premier provider of ... in Maryland – its Bethesda location. Amada franchise partner Steve Schultz ... technology consultant to many of the largest construction firms in the Mid-Atlantic region. ...
(Date:10/9/2015)... , ... October 09, 2015 , ... Smanos was featured ... coolest technology products available to consumers. Scott Steinberg, a technology expert and special reporter ... perfect for any home or dorm. , In this day and age it’s more ...
Breaking Medicine News(10 mins):
... it for 6 months, study finds , , TUESDAY, March 10 ... many overweight/obese blacks lose 5 percent or more of their ... for at least six months. , The study included 35 ... mass index (BMI) of 36. They took part in a ...
... Insight in IndustrySACRAMENTO, Calif., March 10 Donna ... of experience, has joined Alliance Seating & ... growing accredited complex rehab companies. Cole is an ... Calif., for ASM ( ) and provides ...
... Glancy Brings Variety of Experience with Complex Rehab MarketDETROIT, ... with more than 12 years of experience, has joined ... the nation,s fastest growing accredited complex rehab companies. Glancy ... Detroit, Mich., for ASM ( ) and provides ...
... and regulation for the European Union, has approved a ... type of bone cancer. The approval is based on ... Texas M. D. Anderson Cancer Center and a national ... immune-based therapy, that when combined with chemotherapy, resulted in ...
... March 10 CPC of America, Inc. (OTC ... development of therapeutic devices that enhance the quality ... that it is actively pursuing the development of ... of its global commercialization strategy for MedClose(TM). ...
... after reports find a connection, , , TUESDAY, March 10 (HealthDay ... heart disease -- can work together to speed dementia and ... One expert thinks these papers, published in the March issue ... people can take steps to reduce their risk of developing ...
Cached Medicine News:
B-Hemoglobin test system provide quick, simple and reliable quantitative hemoglobin results. It has unbreakable, disposable cuvette which collect the exact amount of blood and mixes the sample with t...
... The Variant hemoglobin ... fast, accurate testing for ... screening, beta-thalassemia testing, hemoglobinopathy ... from a single test. ...
AcT 5diff OV enables low-volume labs to advance to 5-part differential analysis at an affordable price. This analyzer delivers accurate test results and a user-friendly software interface in a compac...
... LH 755 simplifies and automates ... expert automation and advanced technologies ... reliable, accurate results every time. ... slide quality with its slide-on-slide ...
Medicine Products: